Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy

15 May 2013

Abstract excerpt

Neuronal nitric oxide synthase (nNOS) membrane delocalization contributes to the pathogenesis of Duchenne muscular dystrophy (DMD) by promoting functional muscle ischemia and exacerbating muscle injury during exercise. We have previously shown that supra-physiological expression of nNOS-binding mini-dystrophin restores normal blood flow regulation and prevents functional ischemia in transgenic mdx mice, a DMD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exercise and Physiological Responses
Share to Muscle Physiology and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23681067
DOI: 10.1093/hmg/ddt224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophyPMID 23681067Read ↗

Dystrophin Threshold Level Necessary for Normalization of Neuronal Nitric Oxide Synthase, Inducible Nitric Oxide Synthase, and Ryanodine Receptor-Calcium Release Channel Type 1 Nitrosylation in Golden Retriever Muscular Dystrophy DystrophinopathySemantic proximity Read ↗

Systemic human <i>minidystrophin</i> gene transfer improves functions and life span of dystrophin and dystrophin/utrophin‐deficient miceSemantic proximity Read ↗

Dual S100A1 and ARC gene therapy as a treatment for DMD cardiomyopathySemantic proximity Read ↗

Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular DystrophySemantic proximity Read ↗

Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophinSemantic proximity Read ↗

Improving angiogenesis ameliorates the efficacy of ASO-based exon-skipping for the treatment of Duchenne muscular dystrophySemantic proximity Read ↗

Adeno-Associated Virus Vector-Mediated Minidystrophin Gene Therapy Improves Dystrophic Muscle Contractile Function in <i>mdx</i> MiceSemantic proximity Read ↗

Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/mdx MiceSemantic proximity Read ↗

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscleSemantic proximity Read ↗

The root cause of Duchenne muscular dystrophy is the lack of dystrophin in smooth muscle of blood vessels rather than in skeletal muscle per seSemantic proximity Read ↗

Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.Semantic proximity Read ↗

Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.